Out Too Soon
My real name is King Julian ;)
- Joined
- 26 March 2006
- Posts
- 664
- Reactions
- 1
At the risk of talking to myself
View attachment 34034
Hit a high of $2.70 today
(wish incredible charts would lower their subscription pricethis chart is delayed by 16 hrs because it's just not worth $18mth to me )
Well the last couple of days have been good for PXS holders- stock now trading at $2.83, up 33cents in 2 days. Positive phase III trial results attracted buyers...finally. Here's hoping PXS continues to climb. I've watched my shares in this company go sideways for 6 long months- this recent news has broken the monotony if nothing else!
"trial results attracted buyers...finally"
What an annoying pasttime share trading is
Got out again before the latest take off purely because it has been frustrating waiting 6 mths for ppl to wake up & take notice. Small profit but out too soon as per usual
Waiting for a retracement that hopefully wont be followed by any 6 mth doldrums
Looking very promising from here and plenty of news drivers due out most notably the US trial results for bronchitol, price action and previous tests suggest a good result.
Hi people
any ideas why PXS has dropped massively to 1.965
i thought the news was all good ??? not what i was expecitng at all
No idea, obviously higher expectations were factored in on this. And also just maybe, like Metal Storm, the US will not back something that is not thier idea or that they cannot dominate the rights over.
So much for my "good punt" idea the other day.
Just shows that the old addage of "DO YOUR OWN RESEARCH" is absolutely paramount. Had not been following it for 12 months now, so just shows.
EU Regulator Recommends Approval of Pharmaxis’s Bronchitol
QBy Makiko Kitamura - Oct 21, 2011 10:48 PM GMT+1100 inShare2More
Business Exchange Buzz up! Digg Print Email Pharmaxis Ltd. (PXS), the Australian developer of an experimental treatment for cystic fibrosis, won a recommendation from a regulatory panel of the European Medicines Agency to market the company’s most-advanced drug.
The Committee for Medicinal Products for Human Use recommended Bronchitol as an add-on therapy for adult cystic fibrosis patients, reversing an earlier decision, the agency said today in a statement.
Bronchitol is an inhaled treatment designed to treat cystic fibrosis, an inherited disorder that causes build-up of sticky mucus in the airways, leading to lung damage and infections that can kill patients before they turn 40. Australian regulators approved the drug in February.
Pharmaxis shares were placed on a trading halt in Australia on Oct. 17 ahead of the recommendation. The stock fell 74 percent on May 25 after the European panel initially voted against approval of Bronchitol.
To contact the reporters on this story: Makiko Kitamura in London at mkitamura1@bloomberg.net
To contact the editor responsible for this story: Phil Serafino at pserafino@bloomberg.net
Cannot understand that there has not been a mention on this stock for some time.
Got myself back in a week ago at .86 and with the affirmation since of the CMPH we will have a big liftoff come Monday.
I wanted to play it but I didn't know enough about the product to beat the market. And by the time I read up they're already halted.
Very good outcome for PXS and yourself. Will probably double on Monday. It will be interesting to see if they go back to their pre-plunge levels.
Thanks skc, could well attain that soon. The open should be very interesting indeed.
Latest press will certainly turn some eyes to it when it goes back into trade today.
http://www.theaustralian.com.au/bus...ic-fibrosis-drug/story-fn91v9q3-1226174573303
http://www.smh.com.au/business/pharmaxis-set-for-share-lift-20111023-1mef3.html
We use cookies and similar technologies for the following purposes:
Do you accept cookies and these technologies?
We use cookies and similar technologies for the following purposes:
Do you accept cookies and these technologies?